Robert Tucker, MD
Family Medicine · Little Rock, ARNPI 1205829710
Payments from drug & device makers
Across 326 payments — averaging $14.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$679
- AbbVie$677
- GSK$651
- Amgen$625
- Takeda Pharmaceuticals U.S.A., Inc.$330
- Lilly USA, LLC$243
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,645100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 43 | $679 |
| AbbVie(2 entities) | 45 | $677 |
| GSK | 51 | $651 |
| Amgen(2 entities) | 44 | $625 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $330 |
| Lilly USA, LLC | 19 | $243 |
| Amarin Pharma, Inc. | 16 | $209 |
| Novo Nordisk | 13 | $182 |
| Merck | 11 | $148 |
| Pfizer | 11 | $145 |
| Teva Pharmaceuticals USA, Inc. | 6 | $73 |
| Novartis | 5 | $66 |
| AstraZeneca | 4 | $62 |
| Boehringer Ingelheim | 4 | $61 |
| Biohaven Pharmaceuticals, Inc. | 4 | $52 |
| Bausch Health US, LLC | 2 | $46 |
| Genentech USA, Inc. | 3 | $40 |
| Shire North American Group Inc | 3 | $39 |
| Sanofi-aventis U.S. LLC | 3 | $38 |
| Bayer | 3 | $37 |
| Kyowa Kirin, Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Vertical Pharmaceuticals, LLC | 2 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Tris Pharma Inc | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Nevro Corp. | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
How this compares
$4,645 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 189 | $193,329 |
| EliquisApixaban | 101 | $91,781 |
| JardianceEmpagliflozin | 75 | $57,142 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $37,499 |
| XareltoRivaroxaban | 45 | $33,689 |
| TrulicityDulaglutide | 21 | $21,756 |
| MultaqDronedarone Hcl | 16 | $19,722 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $17,976 |
| JanuviaSitagliptin Phosphate | 18 | $17,776 |
| FarxigaDapagliflozin Propanediol | 21 | $17,274 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $16,952 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $15,118 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $11,582 |
| Bisoprolol Fumarate | 316 | $9,450 |
| Levothyroxine Sodium | 815 | $8,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $182 | $193,329189 claims |
| PfizerEliquis | $145 | $91,781101 claims |
| Boehringer IngelheimJardiance | $61 | $57,14275 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $651 | $55,47590 claims |
| MerckJanuvia, Janumet | $148 | $34,72941 claims |
| Johnson & JohnsonXarelto | $15 | $33,68945 claims |
| Lilly USA, LLCTrulicity | $243 | $21,75621 claims |
| Sanofi-aventis U.S. LLCMultaq | $38 | $19,72216 claims |
| AstraZenecaFarxiga | $62 | $17,27421 claims |
| AbbVieSavella, Synthroid | $677 | $9,77880 claims |
| Astellas Pharma US IncMyrbetriq | $679 | $7,32711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Little Rock
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Senthil RaghavanLittle Rock$496K
- Benny GreenLittle Rock$150K
- Lee NaylesLittle Rock$114K
- Steve SimpsonLittle Rock$34K
- Harold BettonLittle Rock$18K
- Sanjay DassLittle Rock$14K
- Benjamin McDonaldLittle Rock$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.